ChromaDex announces results of new pilot clinical trial showing anti-inflammatory effects of nicoti-namide riboside (NR) supplementation

摘要

CHROMADEX CORP HAS announced results of the 18th clinical trial on its flagship Niagen? (patented nicotinamide riboside, or "NR") ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation. The study investigated the anti-inflammatory effects of ChromaDex's proprietary NR ingredient in mono-cytes (a type of white blood cell) extracted from two groups: young, healthy subjects and patients diagnosed with systemic lupus erythematosus (SLE). The study was conducted as part of the ChromaDex External Research Program (CERP?) and adds to a growing body of clinical evidence supporting the potential anti-inflammatory effects of NR supplementation. Results showed that increasing NAD+ levels through NR supplementation reduced Type-Ⅰ interferon (IFN) signaling (which plays an important role in the human immune response) in human monocytes both in vivo in a young, healthy population and ex vivo in monocytes extracted from control subjects and SLE patients.